Andrew Jack

Summary

Affiliation: Financial Times
Country: London

Publications

  1. ncbi request reprint Obesity plan lacks foresight
    Andrew Jack
    Financial Times, London SE1 9HL, UK
    Lancet 370:1528-9. 2007
  2. ncbi request reprint Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:3295-301. 2006
  3. pmc Counterfeit medicines. Bitter pills
    Andrew Jack
    Financial Times, London
    BMJ 335:1120-1. 2007
  4. pmc Balancing Big Pharma's books
    Andrew Jack
    Financial Times, London
    BMJ 336:418-9. 2008
  5. pmc Drug pricing: No cure, no cost
    Andrew Jack
    Financial Times, London
    BMJ 335:122-3. 2007
  6. pmc Donors agree financial arrangement to stimulate vaccine development
    Andrew Jack
    BMJ 336:797. 2008
  7. ncbi request reprint Organisation of neoplastic haematopathology services: a UK perspective
    Andrew Jack
    Haematological Malignancy Diagnostic Service, Department of Haematology, Leeds Teaching Hospital, NHS Trust, United Kingdom
    Pathology 37:479-92. 2005
  8. pmc Drug companies' lobbying of ministers has little effect on NICE
    Andrew Jack
    BMJ 333:719. 2006
  9. pmc Too close for comfort?
    Andrew Jack
    BMJ 333:13. 2006
  10. pmc Europe's drug companies are better than those in US in making drugs accessible to poor countries
    Andrew Jack
    BMJ 336:1396. 2008

Detail Information

Publications10

  1. ncbi request reprint Obesity plan lacks foresight
    Andrew Jack
    Financial Times, London SE1 9HL, UK
    Lancet 370:1528-9. 2007
  2. ncbi request reprint Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:3295-301. 2006
    ..52; P = .011). This is the first trial showing that in relapsed/resistant FL rituximab maintenance considerably improves PFS not only after CHOP but also after R-CHOP induction...
  3. pmc Counterfeit medicines. Bitter pills
    Andrew Jack
    Financial Times, London
    BMJ 335:1120-1. 2007
  4. pmc Balancing Big Pharma's books
    Andrew Jack
    Financial Times, London
    BMJ 336:418-9. 2008
  5. pmc Drug pricing: No cure, no cost
    Andrew Jack
    Financial Times, London
    BMJ 335:122-3. 2007
  6. pmc Donors agree financial arrangement to stimulate vaccine development
    Andrew Jack
    BMJ 336:797. 2008
  7. ncbi request reprint Organisation of neoplastic haematopathology services: a UK perspective
    Andrew Jack
    Haematological Malignancy Diagnostic Service, Department of Haematology, Leeds Teaching Hospital, NHS Trust, United Kingdom
    Pathology 37:479-92. 2005
    ....
  8. pmc Drug companies' lobbying of ministers has little effect on NICE
    Andrew Jack
    BMJ 333:719. 2006
  9. pmc Too close for comfort?
    Andrew Jack
    BMJ 333:13. 2006
  10. pmc Europe's drug companies are better than those in US in making drugs accessible to poor countries
    Andrew Jack
    BMJ 336:1396. 2008